Clinical Trials Sponsored by Boehringer Ingelheim

Total 2529 results

Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Healthy

Germany
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Healthy

Belgium
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy
Boehringer Ingelheim

Recruiting

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Kidney Disease, Chronic

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

Depressive Disorder, Major

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Obesity | Overweight

China
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2)

Obesity | Diabetes Mellitus, Type 2

United States, Belgium, Korea, Republic of, Greece, Australia, Spain, Denmark, China, Poland, Canada, Hungary, Finland, Germany, New Zealand, United Kingdom, Japan, Netherlands, Sweden, Czechia
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Obesity | Non-alcoholic Fatty Liver Disease

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

Spain, United States, Switzerland, Germany
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Recruiting

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Liver Cirrhosis

Germany
Boehringer Ingelheim

Recruiting

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Liver Cirrhosis

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Boehringer Ingelheim

Recruiting

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Lung Diseases, Interstitial

Greece
Boehringer Ingelheim

Recruiting

A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease

Lung Diseases, Interstitial

Germany
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

United States, Japan, Canada
Boehringer Ingelheim

Recruiting

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
Boehringer Ingelheim

Not yet recruiting

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Obesity
Boehringer Ingelheim

Recruiting

INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Lung Diseases, Interstitial

Czechia, Switzerland, Romania, Bulgaria, Poland
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Spain, Korea, Republic of, China, Israel, Germany, Japan, Singapore, Australia, United Kingdom, Austria, Netherlands, France, Portugal, Sweden, Italy, Belgium
Boehringer Ingelheim

Completed

Real-world Study of Dedifferentiated Liposarcoma Patients in China

Dedifferentiated Liposarcoma

China
Boehringer Ingelheim

Completed

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

Lung Diseases, Interstitial

China
Boehringer Ingelheim

Completed

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States, Germany, Sweden, Finland, Israel, Poland, Mexico, Croatia
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Neoplasms

United States, Canada, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Crohn Disease

United States, Belgium, Germany, Hungary, Spain, United Kingdom, Denmark, Czechia, Poland, Italy, Netherlands
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

Schizophrenia

United States
Boehringer Ingelheim

Completed

Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Active, not recruiting

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Lung Diseases, Interstitial

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood

Healthy

Japan
Boehringer Ingelheim

Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Carcinoma, Non-Small-Cell Lung

Spain, Israel, Italy, Austria, Czechia, Greece, Australia, Poland, Hungary, Portugal, Russian Federation
Boehringer Ingelheim

Completed

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Spain, Germany, Italy
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
Boehringer Ingelheim

Terminated

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Neoplasms

United States, Spain, Japan, Netherlands
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany

3

Subscribe